Collegium Pharmaceutical Inc
NASDAQ:COLL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sonadezi Long Binh Share Holding Co
VN:SZB
|
VN |
Collegium Pharmaceutical Inc
Other Equity
Collegium Pharmaceutical Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
Other Equity
$319k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Equity
-$14.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Equity
-$1.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Equity
-$8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Equity
-$4.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Equity
-$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
5%
|
|
Collegium Pharmaceutical Inc
Glance View
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
See Also
What is Collegium Pharmaceutical Inc's Other Equity?
Other Equity
319k
USD
Based on the financial report for Dec 31, 2025, Collegium Pharmaceutical Inc's Other Equity amounts to 319k USD.
What is Collegium Pharmaceutical Inc's Other Equity growth rate?
Other Equity CAGR 1Y
480%
Over the last year, the Other Equity growth was 480%.
